Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Phase III trial for Fortical approved in U.K.

June 28, 1996

C31G research results reported

June 21, 1996

Caverject cleared for marketing in Canada

June 21, 1996

Lilly's Humalog reaches first market

June 21, 1996

Teikoku Hormone reveals novel octadecapeptide

June 21, 1996

Lilly discloses insulin analogues

June 21, 1996

Ceredase approved in Japan

June 21, 1996

Redux launched in U.S.

June 21, 1996

Research results of SomatoKine as catabolism treatment

June 21, 1996

Astra acquires worldwide rights to ALX1-11

June 21, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...